Lehigh County Employees’ Retirement System v. Novo Nordisk A/S, et al.
|Court:||District Court for the District of New Jersey|
|Case Number:||No. 3:17-cv-00209-BRM-LHG|
|Judge:||U.S. District Judge Brian R. Martinotti, U.S. Magistrate Judge Lois H. Goodman|
|Class Period:||02/03/2015 - 02/02/2017|
|Case Contacts:||Salvatore J. Graziano, Katherine M. Sinderson, Adam Hollander, James M. Fee|
This securities class action was filed on behalf of investors who purchased American Depositary Receipts (“ADRs”) of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) during the period from February 3, 2015 to February 2, 2017, inclusive (the “Class Period”), against Novo Nordisk and certain of its senior executives (collectively, “Defendants”). The action alleges claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
Novo Nordisk is a pharmaceutical company that primarily produces insulin and other diabetes-treatment drugs. Only a few other companies manufacture insulin-based medicines. The Complaint alleges that Novo Nordisk and the other three largest insulin manufacturers entered into an improper, collusive agreement to increase the prices of their insulin drugs, as evidenced by synchronized, skyrocketing prices for the insulin products over the past decade. As a result, Novo Nordisk reported impressive revenue throughout the Class Period.
Throughout the Class Period, Defendants told investors that the Company’s sales and profits would continue to grow significantly. Although Novo Nordisk’s competitors told investors that their insulin-related revenues would diminish as a result of pricing pressures from pharmacy benefit managers (“PBMs”) who purchase drugs from pharmaceutical companies, Novo Nordisk assured investors that its sales and profits would continue to grow substantially.
In truth, Novo Nordisk faced the same pricing pressures as its competitors, which was disclosed to the market beginning on August 5, 2016, when the Company announced disappointing earnings and lowered sales and growth forecasts. Defendants nevertheless reassured investors that the Company would grow its profits at a 10% rate. The price of Novo Nordisk’s ADRs dropped significantly on that disclosure, and again on August 8, 2016 on reports that there would be no quick rebound from the Company’s stagnating growth. Finally, on October 28, 2016, Novo Nordisk cut its long-term profit growth forecasts by 50%, specifically citing increased pricing pressures on diabetes drugs, and also announced that it received a Civil Investigative Demand from the U.S. Attorney’s Office for the Southern District of New York concerning the Company’s insulin drugs and relationships with PBMs. On that news, Novo Nordisk ADRs dropped by 13%, the Company’s largest price decline in more than 14 years.
After the close of the Class Period, on November 3, 2016, Senator Bernie Sanders and Representative Elijah Cummings called on federal antitrust regulators to probe illegal collusion by Novo Nordisk and the three other major insulin manufacturers. Novo Nordisk has since pledged to limit all future drug list price increases.
On June 1, 2017, the Court entered an order appointing (i) Lehigh County Employees’ Retirement System; (ii) Boston Retirement System; (iii) Oklahoma Firefighters Pension and Retirement System; and (iv) Central States, Southeast and Southwest Areas Pension Fund as Co-Lead Plaintiffs. In that order, the Court also appointed BLB&G and co-counsel as Co-Lead Counsel for the Class.
Co-Lead Plaintiffs filed their consolidated amended complaint on August 4, 2017. Defendants moved to dismiss the complaint on October 3, 2017. Following briefing and argument, on August 16, 2018, the Court denied Defendants’ motion to dismiss in its entirety.
Following the Court’s ruling denying Defendants’ motion to dismiss, the parties have entered discovery.
On April 1, 2019, Plaintiffs filed their motion for class certification. Under the schedule entered by the Court, briefing on the class certification motion will be completed June 3, 2019. Fact discovery is set to close on March 2, 2020, which all discovery to close on June 3, 2020 and any summary judgment motions due on July 3, 2020.
If you wish to discuss this action or have any questions concerning your rights or interests, please contact Salvatore J. Graziano, Katherine M. Sinderson, or Adam D. Hollander at 212-554-1400.
Other Cases of Interest
The Boeing Company
Northern District of Illinois Eastern Division John C. Browne, Abe Alexander, James M. Fee
Kraft Heinz Company
Northern District of Illinois Salvatore J. Graziano, Katherine M. Sinderson, Abe Alexander, Kyle Panton, Nicholas Gersh
Southern District of New York, Salvatore J. Graziano, Katherine M. Sinderson, Adam Hollander
District of Delaware Hannah Ross, Lauren McMillen Ormsbee, Richard D. Gluck, Katherine M. Sinderson, Julia Tebor, Jesse L. Jensen
Southern District of New York John Rizio-Hamilton, James M. Fee
MF Global Holdings Limited Securities Litigation
Southern District of New York Salvatore J. Graziano, Hannah Ross, Jai K. Chandrasekhar
Merck & Co., Inc. (Vioxx-Related)
District of New Jersey Salvatore J. Graziano, David Wales, Katherine M. Sinderson, Adam H. Wierzbowski
Middle District of Louisiana John C. Browne, Adam H. Wierzbowski, Adam Hollander, Julia Tebor
Spectrum Brands Holdings, Inc.
Western District of Wisconsin Avi Josefson, Katherine M. Sinderson, Jai K. Chandrasekhar, Matthew Traylor
Southern District of California Salvatore J. Graziano, Jeroen van Kwawegen, Jonathan D. Uslaner, Richard D. Gluck, Rebecca E. Boon, Kyle Panton, Lauren M. Cruz